Citadel Advisors
LFCR icon

Citadel Advisors’s Lifecore Biomedical LFCR Stock Holding History

Citadel Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,300
Closed -$38.3K – 14365
2026
Q1 		$38.3K Buy
+10,300
New +$71.1K ﹤0.01% 12505
2024
Q3 		– Sell
-3,600
Closed -$18.5K – 14797
2024
Q2 		$18.5K Sell
3,600
-12,400
-78% -$73.4K ﹤0.01% 12713
2024
Q1 		$85K Buy
+16,000
New +$114K ﹤0.01% 11578
2023
Q4 		– Sell
-44,400
Closed -$335K – 14831
2023
Q3 		$335K Sell
44,400
-6,300
-12% -$57.6K ﹤0.01% 8940
2023
Q2 		$490K Buy
50,700
+46,100
+1,002% +$282K ﹤0.01% 7985
2023
Q1 		$17.4K Sell
4,600
-2,100
-31% -$11.7K ﹤0.01% 13159
2022
Q4 		$43.4K Buy
+6,700
New +$55.2K ﹤0.01% 12300
2022
Q1 		– Sell
-10,400
Closed -$115K – 14155
2021
Q4 		$115K Sell
10,400
-200
-2% -$1.94K ﹤0.01% 12575
2021
Q3 		$98K Sell
10,600
-12,300
-54% -$134K ﹤0.01% 12900
2021
Q2 		$258K Buy
22,900
+10,300
+82% +$119K ﹤0.01% 11629
2021
Q1 		$134K Buy
+12,600
New +$142K ﹤0.01% 12176

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Citadel Advisors's LFCR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 98,870 shares worth $519K. The stake represents ﹤0.01% of the portfolio and ranks #9773 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LFCR as recently as Q4 2025.

Citadel Advisors first reported a position in LFCR in Q3 2013 and has held it in 29 quarters since. The position peaked at $695K in Q1 2014. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Citadel Advisors held 98,870 shares of Lifecore Biomedical worth $519K as of Q2 2026.
  • Lifecore Biomedical was a new Citadel Advisors position in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9773 holding.
  • Citadel Advisors first reported a position in Lifecore Biomedical in Q3 2013 and has held it in 29 quarters since.
  • Citadel Advisors's Lifecore Biomedical position peaked at $695K in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.